Global Pharmatech Inc
Global Pharmatech Inc is a pharmaceutical company that develops and commercializes prescription drugs, generating revenue primarily through product sales.
Business. Global Pharmatech Inc (GBLP.PK) is a pharmaceutical company operating within the Healthcare sector. The firm engages in the development and sale of pharmaceutical products. Specific details regarding its operating segments, headquarters location, and primary stock exchange listings are not available in the provided data. Consequently, the company is described at the industry level without geographic or segmental breakdowns.
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
Global Pharmatech Inc (GBLP.PK) is a pharmaceutical company operating within the Healthcare sector. The firm engages in the development and sale of pharmaceutical products. Specific details regarding its operating segments, headquarters location, and primary stock exchange listings are not available in the provided data. Consequently, the company is described at the industry level without geographic or segmental breakdowns.
Global Pharmatech Inc has a current ratio of 6.72, indicating strong short-term liquidity, but its operating cash flow of -228,000 USD and negative net income of -274,000 USD suggest ongoing operational challenges. The company's debt-to-equity ratio of 0.23 reflects a relatively conservative capital structure, with long-term debt of 2,865,000 USD compared to total equity of 12,236,000 USD.
Profitability metrics are concerning, with a return on equity of -2.24%, far below the typical performance of pharmaceutical firms. The company's operating income of -280,000 USD and net loss of -274,000 USD indicate a significant deviation from industry norms, where positive returns are expected.
The company's revenue of 335,000 USD is derived from a single business segment, with no disclosed geographic diversification. This concentration increases exposure to market-specific risks and limits growth potential.
Looking ahead, the company's revenue is expected to remain flat or decline, with no clear drivers of growth identified in the financial data. The absence of capital expenditure and the negative operating cash flow suggest a lack of investment in future capacity or innovation.
Risk factors include liquidity concerns, as the company has negative net cash after subtracting total debt. The risk of dilution is currently low, but the company's financial position may necessitate equity issuance in the future.
Recent filings and transcripts have not disclosed any material events or strategic shifts that would alter the company's trajectory. The lack of analyst coverage and limited financial transparency further complicate the assessment of future performance.
- Global Pharmatech Inc is experiencing significant financial distress, with negative operating and net income.
- The company's capital structure is relatively conservative, but its liquidity position is at risk due to negative net cash.
- Revenue is concentrated in a single segment, with no geographic diversification disclosed.
- There are no clear signs of near-term growth or strategic investment in the company's operations.
- The risk of dilution is currently low, but the company's financial position may require equity issuance in the future.
Bull / Bear case
Generated · model-assistedIn focus — financials by report
Revenue $728.0k, +21,5% YoY; Operating income +91,0% YoY.
- ▍Revenue $728.0k, +21,5% YoY
- ▍Operating income +91,0% YoY
- ▍Net income +91,6% YoY
- ▍Net margin -12.6%
Revenue $702.0k, +49,0% YoY; Operating income −28,3% YoY.
- ▍Revenue $702.0k, +49,0% YoY
- ▍Operating income −28,3% YoY
- ▍Net income +21,9% YoY
- ▍Net margin -30.5%
Revenue $1.2M, +92,5% YoY; Operating income −84,9% YoY.
- ▍Revenue $1.2M, +92,5% YoY
- ▍Operating income −84,9% YoY
- ▍Net income −25,9% YoY
- ▍Net margin -122.4%
Revenue $599.0k; Operating income -$255.0k.
- ▍Revenue $599.0k
- ▍Operating income -$255.0k
- ▍Net margin -182.1%
Revenue $471.0k; Operating income -$173.0k.
- ▍Revenue $471.0k
- ▍Operating income -$173.0k
- ▍Net margin -58.2%
Revenue $638.0k; Operating income -$936.0k.
- ▍Revenue $638.0k
- ▍Operating income -$936.0k
- ▍Net margin -187.1%
Revenue $2.8M, +32,4% YoY; Operating income −95,4% YoY.
- ▍Revenue $2.8M, +32,4% YoY
- ▍Operating income −95,4% YoY
- ▍Net income −167,3% YoY
- ▍Net margin -117.0%
Valuation TTM
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Estimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- Net cash is negative after subtracting total debt.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Capex To Revenuecapital_expenditure / revenue
- Return On Equitynet_income / total_equity
- Debt To Equity(short_term_debt + long_term_debt) / total_equity
- Cash Conversion Ratiooperating_cash_flow / net_income
- Global Pharmatech Inc Market data — financials · 2026-05-28
- Global Pharmatech Inc Market data — analyst estimates · 2026-05-28